MedPath

Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Phase 3
Terminated
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
First Posted Date
2019-04-10
Last Posted Date
2021-10-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT03909295
Locations
🇯🇵

Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Phase 3
Completed
Conditions
Chronic Spontaneous Urticaria
Interventions
First Posted Date
2019-04-09
Last Posted Date
2025-03-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
66
Registration Number
NCT03907878
Locations
🇯🇵

Novartis Investigative Site, Hiroshima, Japan

AScalate: Treat-to-target in Axial Spondyloarthritis

Phase 3
Completed
Conditions
Axial Spondyloarthritis
Interventions
Biological: Secukinumab/Adalimumab-Biosimilar
Other: Standard-of-care
First Posted Date
2019-04-08
Last Posted Date
2025-04-29
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
304
Registration Number
NCT03906136
Locations
🇩🇪

Novartis Investigative Site, Ulm, Germany

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Phase 2
Completed
Conditions
Sjögren Syndrome
Interventions
Other: Placebo
First Posted Date
2019-04-05
Last Posted Date
2023-09-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
273
Registration Number
NCT03905525
Locations
🇬🇧

Novartis Investigative Site, Manchester, United Kingdom

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 2
Completed
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
First Posted Date
2019-03-29
Last Posted Date
2024-06-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
13
Registration Number
NCT03896152
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1
Active, not recruiting
Conditions
Nasopharyngeal Carcinoma
Microsatellite Stable Colorectal Cancer
Carcinoma, Non-Small-Cell Lung
Melanoma
Triple Negative Breast Cancer
Interventions
First Posted Date
2019-03-27
Last Posted Date
2025-05-04
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
98
Registration Number
NCT03891953
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Not Applicable
Completed
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Diagnostic Test: Blood draw for Lp(a)
First Posted Date
2019-03-25
Last Posted Date
2022-01-28
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
49001
Registration Number
NCT03887520
Locations
🇻🇳

Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Phase 2
Active, not recruiting
Conditions
B-Cell Acute Lymphoblastic Leukemia
Interventions
Biological: CTL019
First Posted Date
2019-03-15
Last Posted Date
2024-07-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
121
Registration Number
NCT03876769
Locations
🇺🇸

Dana Farber Cancer Institute Dept.of DFCI, Boston, Massachusetts, United States

🇺🇸

Methodist Childrens Hospital ., San Antonio, Texas, United States

🇺🇸

City of Hope National Medical, Duarte, California, United States

and more 30 locations

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1
Terminated
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Biological: Tisagenlecleucel
First Posted Date
2019-03-15
Last Posted Date
2023-01-31
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT03876028
Locations
🇺🇸

University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination

Phase 2
Active, not recruiting
Conditions
Chronic Myeloid Leukemia
Interventions
First Posted Date
2019-03-14
Last Posted Date
2025-05-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
124
Registration Number
NCT03874858
Locations
🇮🇹

Novartis Investigative Site, Novara, Italy

© Copyright 2025. All Rights Reserved by MedPath